HMGA2 expression and response to anthracycline-based preoperative chemotherapy in patients with operable breast cancer

被引：0
|
作者：
Puglisi, F.
Ermacora, P.
Driol, P.
Masolini, P.
Alessi, B.
Pisa, F. E.
Pandolfi, M.
Mansutti, M.
Giancotti, V.
Di Loreto, C.
机构：
[1] Univ Hosp, Udine, Italy
[2] Univ Trieste, Trieste, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.22035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Konecny, Gottfried E.
    Pauletti, Giovanni
    Untch, Michael
    Wang, He-Jing
    Moebus, Volker
    Kuhn, Walther
    Thomssen, Christoph
    Harbeck, Nadia
    Wang, Ling
    Apple, Sophia
    Jaenicke, Fritz
    Slamon, Dennis J.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (02) : 481 - 489
  • [32] Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E. Konecny
    Giovanni Pauletti
    Michael Untch
    He-Jing Wang
    Volker Möbus
    Walther Kuhn
    Christoph Thomssen
    Nadia Harbeck
    Ling Wang
    Sophia Apple
    Fritz Jänicke
    Dennis J. Slamon
    Breast Cancer Research and Treatment, 2010, 120 : 481 - 489
  • [33] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Wang, Zhan
    Chen, Juan
    Zhong, Mei-Zuo
    Huang, Juan
    Hu, Yuan-Ping
    Feng, De-Yun
    Zhou, Zhi-Jiao
    Luo, Xiao
    Liu, Zhao-Qian
    Jiang, Wu-Zhong
    Zhou, Wei-Bing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 535 - 543
  • [34] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Vargas-Roig, L. M.
    Cuello-Carrion, F. D.
    Fernandez-Escobar, N.
    Daguerre, P.
    Leuzzi, M.
    Ibarra, J.
    Gago, F. E.
    Nadin, S. B.
    Ciocca, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Zhan Wang
    Juan Chen
    Mei-Zuo Zhong
    Juan Huang
    Yuan-Ping Hu
    De-Yun Feng
    Zhi-Jiao Zhou
    Xiao Luo
    Zhao-Qian Liu
    Wu-Zhong Jiang
    Wei-Bing Zhou
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 535 - 543
  • [36] Cardioprotective effect of Trimetazidine in patients with early breast cancer receiving anthracycline-based chemotherapy
    Delle Donne, M. G.
    Iannielli, A.
    Capozza, P.
    De Caterina, R.
    Marzilli, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 880 - 880
  • [37] Association of cardiac energetics and plasma biomarkers with anthracycline-based chemotherapy in breast cancer patients
    Oikonomidou, Olga
    Macnaught, Gillian Macnaught
    Rodgers, Christopher T.
    Clarke, William
    Cooper, Annette
    McVicars, Heather
    Turnbull, Arran K.
    Mirsadraee, Saeed
    Semple, Scott
    Denvir, Martin
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors
    Serrano, Jose M.
    Gonzalez, Iria
    Del Castillo, Silvia
    Muniz, Javier
    Morales, Luis J.
    Moreno, Fernando
    Jimenez, Rosa
    Cristobal, Carmen
    Graupner, Catherine
    Talavera, Pedro
    Curcio, Alejandro
    Martinez, Paula
    Guerra, Juan A.
    Alonso, Joaquin J.
    ONCOLOGIST, 2015, 20 (08): : 864 - 872
  • [39] Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
    Mina, Alain
    Rafei, Hind
    Khalil, Maya
    Hassoun, Yasmine
    Nasser, Zeina
    Tfayli, Arafat
    BMC CANCER, 2015, 15
  • [40] RESPONSE RATE TO INDUCTION ANTHRACYCLINE-BASED CHEMOTHERAPY IN INFLAMMATORY BREAST CARCINOMA
    Kolarevic, D.
    Tomasevic, Z.
    Jelic, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 37
12345